Hem/Onc News

Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer On September 20, the US Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak, […]

Progressive Differentiated Thyroid Cancer: Best Use of the Tyrosine Kinase Inhibitors

Abstract: Thyroid cancer has one of the best overall survival rates among all malignancies, but it has a high incidence. There are various subtypes of thyroid cancer. […]